Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Cushing Syndrome I: Introduction

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Cushing Syndrome II: Pathophysiology

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Fracture Phenotypes in Women and Men of 50 Years and Older with a Recent Clinical Fracture.

Current osteoporosis reports·2024

Same author

The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena.

Archives of osteoporosis·2024

Same author

Course and predictors of upper leg muscle strength over 48 months in subjects with knee osteoarthritis: Data from the osteoarthritis initiative.

Osteoarthritis and cartilage open·2022

Same author

Evaluation of treatment outcome using the Patient Specific Functional Scale in knee osteoarthritis patients undergoing multidisciplinary rehabilitation.

Osteoarthritis and cartilage open·2022

Same author

Determinants of pain and activity limitations in foot osteoarthritis: An exploratory cross-sectional study in the Amsterdam-foot cohort.

Osteoarthritis and cartilage open·2022

Same author

In RA patients without prevalent CVD, incident CVD is mainly associated with traditional risk factors: A 20-year follow-up in the CARRÉ cohort study.

Seminars in arthritis and rheumatism·2022

Search research articles

Related Experiment Video

Updated: May 28, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Glucocorticoid-induced osteoporosis.

D den Uyl¹, I E M Bultink, W F Lems

¹VU University Medical Center, Department of Rheumatology, 1081 HV Amsterdam, The Netherlands. d.denuyl@vumc.nl

Clinical and Experimental Rheumatology

|October 25, 2011

Summary

This summary is machine-generated.

Glucocorticoid-induced osteoporosis increases fracture risk. This review covers its mechanisms, risk identification, and the 2010 American College of Rheumatology (ACR) guidelines for prevention and treatment.

Related Experiment Videos

Last Updated: May 28, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Area of Science:

Endocrinology
Rheumatology
Bone Metabolism

Background:

Glucocorticoid therapy is essential for many conditions but causes significant bone loss.
Glucocorticoid-induced osteoporosis (GIOP) is a major clinical concern, elevating fracture risk.
Understanding GIOP mechanisms is crucial for effective management.

Purpose of the Study:

To summarize recent advances in understanding GIOP pathogenesis.
To discuss methods for identifying patients at risk of fractures.
To review the 2010 American College of Rheumatology (ACR) guidelines for GIOP prevention and treatment.

Main Methods:

Literature review focusing on recent research in GIOP.
Analysis of current methods for fracture risk assessment.
Evaluation of established and emerging treatment strategies for GIOP.

Main Results:

Recent insights have elucidated key molecular mechanisms driving GIOP.
Effective strategies exist for identifying individuals susceptible to fractures.
The 2010 ACR guidelines provide a framework for GIOP management.

Conclusions:

Further understanding of GIOP pathogenesis may lead to novel therapeutic targets.
Personalized risk assessment and guideline-adherent treatment are vital.
Optimizing glucocorticoid use and managing GIOP are critical for patient outcomes.